ライフサイエンスコーパス: sleep apnea

1 ional cofactors of interest (e.g., age, sex, sleep apnea).

2 italized HF patients with moderate-to-severe sleep apnea.

3 t necessary for most patients with suspected sleep apnea.

4 ealed increased gray matter with obstructive sleep apnea.

5 arotid body (CB) activity may be a driver of sleep apnea.

6 d cognitive consequences seen in obstructive sleep apnea.

7 ted to a presymptomatic stage of obstructive sleep apnea.

8 peutic intervention for preventing CB-driven sleep apnea.

9 aberrations in their signaling could lead to sleep apnea.

10 a new pharmacologic therapy for obstructive sleep apnea.

11 l-controlled type 2 diabetes and obstructive sleep apnea.

12 sis on children with more severe obstructive sleep apnea.

13 omic factors and the presence of obstructive sleep apnea.

14 etes mellitus, hypertension, and obstructive sleep apnea.

15 ejection fraction and predominantly central sleep apnea.

16 etes mellitus, hypertension, and obstructive sleep apnea.

17 rol network whose dysfunction contributes to sleep apnea.

18 atus, pack-years, systemic hypertension, and sleep apnea.

19 onitor for 1 night to assess for obstructive sleep apnea.

20 measurements of the severity of obstructive sleep apnea.

21 uption and adverse autonomic consequences of sleep apnea.

22 Three of the four also had sleep apnea.

23 unambiguously to distinguish the severity of sleep apnea.

24 ssing physiological variation in obstructive sleep apnea.

25 s, hypogonadism, intellectual disability and sleep apnea.

26 simulating a severe condition of obstructive sleep apnea.

27 rtension, hyperlipidemia, venous stasis, and sleep apnea.

28 hich may be partially explained by untreated sleep apnea.

29 l its potential for reduction of obstructive sleep apneas.

30 s index >/=25kg/m(2) (+1 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 poin

31 TBI, 29% of patients have insomnia, 25% have sleep apnea, 28% have hypersomnia, and 4% have narcoleps

32 ion (2.94 vs 2.80, P = .75), and obstructive sleep apnea (3.29 vs 2.83, P = .50).

33 ated blood carbon dioxide levels, as seen in sleep apnea [3].

34 s with OHS and coexistent severe obstructive sleep apnea, 4) patients hospitalized with respiratory f

35 ity revenue, 48 cases of cure of obstructive sleep apnea, 44 cases of remission of type 2 diabetes me

36 ke time, reminiscent of clinical findings in sleep apnea [5, 6].

37 QR, 4-6, vs 3; IQR, 2-5; P < .001), but less sleep apnea (578 [13.5%] vs 1264 [21.6%]; P < .001).

38 ty in a prospective study of 74,543 cases of sleep apnea (60,125 outpatient, 14,418 inpatient) from t

39 There were no differences in resolution of sleep apnea (62.6% vs 62.0%; P = .77), hypertension (47.

40 ts: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea i

41 29.7%-19.5%), dyslipidemia (14.0%-6.8%), and sleep apnea (9.6%-2.6%) was reduced.

42 critical to the pathogenesis of obstructive sleep apnea, a common and serious sleep-related breathin

43 highly prevalent condition and a hallmark of sleep apnea, a condition that has been associated with i

44 italized HF patients with moderate-to-severe sleep apnea, adding ASV to OMT did not improve 6-month c

45 found to have increased odds of KCN included sleep apnea (adjusted OR, 1.13; 95% CI, 1.00-1.27; P = 0

46 We found a link between obstructive sleep apnea and an elevated risk of stage 3 CKD or highe

47 The association between sleep apnea and atrial fibrillation (AF) has not been ex

48 he evidence that addresses the links between sleep apnea and cardiovascular disease, and research tha

49 empirical bases for considering obstructive sleep apnea and central sleep apnea associated with Chey

50 Given the high prevalence of obstructive sleep apnea and CKD among adults, further investigation

51 sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most adverse event

52 easures showed a reduction in the effects of sleep apnea and improved quality of life.

53 isk factors included sleep disturbances (eg, sleep apnea and insomnia), mental health status (eg, pos

54 nd the common sleep disorders of obstructive sleep apnea and insomnia.

55 bone density; high prevalence of obstructive sleep apnea and its implications; prevalence of mental h

56 However, increased arousals in patients with sleep apnea and other disorders prevent restful sleep an

57 caffeine status, are at risk for obstructive sleep apnea and periodic limb movements in later childho

58 We evaluated associations between sleep apnea and receipt of a disability pension and mort

59 ing high altitude, lung disease, obstructive sleep apnea, and age-related CNS ischemia/hypoxia, our f

60 children with moderate to severe obstructive sleep apnea, and also that even snoring alone affects ne

61 hypertension, dyslipidemia, depression, and sleep apnea, and changes in corresponding laboratory dat

62 ing, obesity, diabetes mellitus, obstructive sleep apnea, and elevated blood pressure predispose to A

63 eaks, patient-ventilator asynchrony, central sleep apnea, and glottic closure.

64 diabetes mellitus, inflammation, obstructive sleep apnea, and others.

65 sleep disorders (e.g., insomnia, obstructive sleep apnea, and parasomnias).

66 pnea (PDSA), which is considered more severe sleep apnea, and self-reported habitual snoring without

67 with obesity, moderate-to-severe obstructive sleep apnea, and serum levels of C-reactive protein (CRP

68 Thirteen male participants with obstructive sleep apnea (apnea-hypopnea index > 5 events/hr) were ad

69 events per hour) and 72 obese patients with sleep apnea (apnea-hypopnea index, 43.5 +/- 28.0 events

70 iratory control system is compromised (e.g., sleep apnea, apnea of prematurity, spinal injury, or mot

71 ciated with myocardial infarcts, obstructive sleep apneas, apneas of prematurity, Rett syndrome, and

72 the diagnosis and management of obstructive sleep apnea are reviewed, as are recent guidelines perta

73 2 diabetes, hypertension, dyslipidemia, and sleep apnea, are very common in the United States, but c

74 sidering obstructive sleep apnea and central sleep apnea associated with Cheyne-Stokes respiration as

75 Central sleep apnea associated with Cheyne-Stokes respiration pr

76 a high prevalence of obstructive and central sleep apnea associated with Cheyne-Stokes respiration.

77 and lifestyle behaviors, severe obstructive sleep apnea associated with increased risk of CKD (hazar

78 apnic COPD undergo screening for obstructive sleep apnea before initiation of long-term NIV (conditio

79 ion, left atrial and ventricular remodeling, sleep apnea, blood pressure, and improved glycemic contr

80 Among patients with obstructive sleep apnea, both CPAP and MADs were associated with red

81 ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality

82 f more symptomatic patients with obstructive sleep apnea, but its effectiveness has not been evaluate

83 es a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory p

84 Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of exces

85 CANCE STATEMENT Individuals with obstructive sleep apnea can breathe adequately when awake but experi

86 t of hypertension, diabetes, and obstructive sleep apnea can reduce atrial fibrillation episodes.

87 , concomitant procedures, diabetes mellitus, sleep apnea, cardiopathy, renal insufficiency, inflammat

88 ypes spans diabetes, renal disease, obesity, sleep apnea, cardiovascular disease, and cognitive disor

89 RATIONALE: Obstructive sleep apnea causes intermittent hypoxemia, hemodynamic f

90 sleep indices: apnea-hypopnea index, central sleep apnea (central apnea index, >/=5 vs. <5), central

91 seous molecule carbon monoxide (CO), exhibit sleep apnea characterized by high apnea and hypopnea ind

92 ale sex, higher body mass index, concomitant sleep apnea, conversion to laparotomy, longer operation

93 Central sleep apnea (CSA) is a highly prevalent, though often un

94 lar disease, aortic aneurysm, Down syndrome, sleep apnea, depression, hyperlipidemia, astigmatism, an

95 onary disease, hyperlipidemia, hypertension, sleep apnea, diabetes mellitus, heart failure, periphera

96 ors, including obesity, physical inactivity, sleep apnea, diabetes mellitus, hypertension, and other

97 tion of medical comorbidities (hypertension, sleep apnea, diabetes, and hyperlipidemia), functional s

98 nsion, diagnoses including obesity, alcohol, sleep apnea, diabetes, chronic obstructive pulmonary dis

99 Only 1.3% of participants reported a sleep apnea diagnosis.

100 ed an insomnia diagnosis and 3.0% reported a sleep apnea diagnosis.

101 as no long-term effects on sleep duration or sleep apnea during childhood.

102 During obstructive sleep apnea, elevation of CO(2) during apneas contribute

103 ellitus, chronic kidney disease, obstructive sleep apnea, etc.

104 WP can detect sleep apnea events in patients with AF.

105 pnea.SIGNIFICANCE STATEMENT Individuals with sleep apnea experience periods of intermittent hypoxia (

106 and as a result individuals with obstructive sleep apnea experience repeated episodes of upper airway

107 provides a clinical overview of Obstructive Sleep Apnea focusing on prevention, diagnosis, treatment

108 treatment option for snoring and obstructive sleep apnea for almost three decades.

109 along with developments in the treatment of sleep apnea, have accumulated in recent years.

110 men and was strongest in those with moderate sleep apnea (hazard ratio, 1.59; 95% confidence interval

111 nsion, increased pulse pressure, obstructive sleep apnea, high-level physical training, diastolic dys

112 l factors that included obesity, obstructive sleep apnea, higher comorbidity, and use of prescription

113 as shown to be accurate for the diagnosis of sleep apnea; however, studies using the WatchPAT device

114 TE were significantly more common, including sleep apnea, hypercholesterolemia, obesity, indicators o

115 struction sites in patients with obstructive sleep apnea hypopnea syndrome (OSAHS).

116 hlights the interactions between obstructive sleep apnea-hypopnea syndrome (OSAHS) and cardiovascular

117 atient generated health data, an obstructive sleep apnea-hypopnea syndrome (OSAHS) monitoring and int

118 y disease, diabetes mellitus, or obstructive sleep apnea (ie, lone AF) undergoing ablation and 25 mat

119 uptake in the genioglossus of patients with sleep apnea in comparison with obese normal subjects wit

120 Early diagnosis and treatment of sleep apnea in patients with atrial fibrillation (AF) is

121 E-HF (Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial results.

122 reat central apnea (CA) occurring at night ("sleep apnea") in patients with systolic heart failure (H

123 her elevations in the obstructive or central sleep apnea index or the presence of Cheyne-Stokes breat

124 Obstructive sleep apnea is a common disorder associated with increas

125 Sleep apnea is a common problem affecting daily function

126 Obstructive sleep apnea is a risk factor for mortality, but its diag

127 Obstructive sleep apnea is a state-dependent disease.

128 Obstructive sleep apnea is associated with considerable health risks

129 Obstructive sleep apnea is associated with higher levels of blood pr

130 ological research indicates that obstructive sleep apnea is associated with increases in the incidenc

131 Central sleep apnea is associated with poor prognosis and death

132 Sleep apnea is common in hospitalized heart failure (HF)

133 Sleep apnea is highly prevalent in patients with cardiov

134 eural circuitry that mediates arousal during sleep apnea is not known.

135 In conclusion, inpatient sleep apnea is related to a higher risk of disability pe

136 f genetic factors in influencing obstructive sleep apnea, its genetic basis is still largely unknown.

137 (pH 7.0) typically found with hypoxia during sleep apnea, M94I resulted in 37% reduction in peak INa

138 Obstructive sleep apnea may be associated with development of CKD th

139 Obstructive sleep apnea may be associated with preclinical thinning

140 isposition, hypertension, diabetes mellitus, sleep apnea, obesity, excessive alcohol, smoking, hypert

141 sk factors (hypertension, diabetes mellitus, sleep apnea, obesity, excessive alcohol, smoking, hypert

142 Central sleep apnea (odds ratio [OR], 2.58; 95% confidence inter

143 ysis, the most significant risk factors were sleep apnea (odds ratio [OR], 3.80; 95% CI, 1.00-14.49;

144 Individuals with sleep apnea often exhibit changes in cognitive behaviors

145 ty about the effects of treating obstructive sleep apnea on glycemic control in patients with type 2

146 ent hypoxia (IH), a principal consequence of sleep apnea, on hippocampal adult neurogenesis remains u

147 propriate, refer patients for evaluation for sleep apnea or asthma.

148 (central apnea index, >/=5 vs. <5), central sleep apnea or Cheyne-Stokes respiration, obstructive ap

149 hypertension, emerging risk factors such as sleep apnea or inflammation, and increasingly well-defin

150 2; 95% confidence interval (CI): 2.58-3.53], sleep apnea (OR 1.49; 95% CI: 1.41-1.58), psychological

151 e 65 years or older (OR, 1.4; P < .001), and sleep apnea (OR, 1.3; P < .001).

152 ) and Cheyne-Stokes respiration with central sleep apnea (OR, 2.27; 95% CI, 1.13-4.56), but not obstr

153 f the following: CHA2DS2-VASc score of >/=2, sleep apnea, or body mass index >30 kg/m(2).

154 ine glycemic control, those with more severe sleep apnea, or those who were adherent to therapy.

155 nd psychological issues, asthma, obstructive sleep apnea, orthopedic problems, and adverse cardiovasc

156 fluid overload, both obstructive and central sleep apnea (OSA and CSA) are common.

157 Obstructive sleep apnea (OSA) affects 17% of women and 34% of men in

158 Obstructive sleep apnea (OSA) affects 8-10% of the population, is ch

159 derlying the association between obstructive sleep apnea (OSA) and Alzheimer's disease is OSA leading

160 Obstructive sleep apnea (OSA) and asthma are highly prevalent chroni

161 nt hypoxia (IH) in patients with obstructive sleep apnea (OSA) and cutaneous melanoma (CM).

162 Obstructive sleep apnea (OSA) and nocturnal hypoxemia are associated

163 Risk factors for obstructive sleep apnea (OSA) and the development of subsequent card

164 Treatment is needed for obstructive sleep apnea (OSA) because untreated OSA can result in se

165 Surgical success for obstructive sleep apnea (OSA) depends on identifying sites of obstru

166 ryngeal factors is important for obstructive sleep apnea (OSA) evaluation.

167 structive pulmonary disease, and obstructive sleep apnea (OSA) exhibit daily variance.

168 A high prevalence of obstructive sleep apnea (OSA) has been reported in Down syndrome (DS

169 iation between periodontitis and obstructive sleep apnea (OSA) has been suggested.

170 ly, the presence and severity of obstructive sleep apnea (OSA) have been defined by the apnea-hypopne

171 An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes ha

172 e 1990s, estimated prevalence of obstructive sleep apnea (OSA) in the United States is 10% for mild O

173 Obstructive sleep apnea (OSA) increases risk of dementia, a relation

174 We determine whether obstructive sleep apnea (OSA) increases serum levels of active TGF-b

175 Obstructive sleep apnea (OSA) is a common disorder associated with i

176 Obstructive sleep apnea (OSA) is a common sleep disorder associated

177 Obstructive sleep apnea (OSA) is a highly prevalent disorder also in

178 Mild obstructive sleep apnea (OSA) is a highly prevalent disorder in adul

179 Obstructive sleep apnea (OSA) is a known risk factor for atheroscler

180 Obstructive sleep apnea (OSA) is a risk factor for type 2 diabetes t

181 Obstructive sleep apnea (OSA) is a sleep disorder characterized by d

182 Obstructive sleep apnea (OSA) is a very prevalent disorder.

183 Obstructive sleep apnea (OSA) is a worldwide disease whose prevalenc

184 Obstructive sleep apnea (OSA) is associated with atrial remodeling,

185 Obstructive sleep apnea (OSA) is associated with hypertension.

186 Although obstructive sleep apnea (OSA) is associated with impaired glucose to

187 Rationale: Obstructive sleep apnea (OSA) is associated with increased cardiovas

188 RATIONALE: Obstructive sleep apnea (OSA) is associated with several pathophysio

189 Obstructive sleep apnea (OSA) is associated with systemic hypertensi

190 t studies have demonstrated that obstructive sleep apnea (OSA) is associated with the development and

191 Obstructive sleep apnea (OSA) is characterized by recurrent upper ai

192 Obstructive sleep apnea (OSA) is common in patients with coronary ar

193 Obstructive sleep apnea (OSA) is common in people with hypertension,

194 Obstructive sleep apnea (OSA) is linked to increased glaucoma risk i

195 Obstructive sleep apnea (OSA) is more common among patients with ast

196 somnography (PSG) for diagnosing obstructive sleep apnea (OSA) is unclear.

197 Obstructive sleep apnea (OSA) is very common but is frequently undia

198 Despite emerging evidence that obstructive sleep apnea (OSA) may cause metabolic disturbances indep

199 racranial hypertension (ICH) and obstructive sleep apnea (OSA) on optic nerve function in children wi

200 dex (REI) in moderate and severe obstructive sleep apnea (OSA) patients requires elucidation.

201 The effect of obstructive sleep apnea (OSA) syndrome in the peripapillary retinal

202 Many adults with obstructive sleep apnea (OSA) use device treatments inadequately and

203 Moderate or severe obstructive sleep apnea (OSA) was defined as a respiratory event ind

204 ) is a hallmark manifestation of obstructive sleep apnea (OSA), a widespread disorder of breathing.

205 syndrome (RLS), 21 patients with obstructive sleep apnea (OSA), and 19 healthy volunteers).

206 at increased risk for developing obstructive sleep apnea (OSA), and both of these conditions are asso

207 Childhood asthma and obstructive sleep apnea (OSA), both disorders of airway inflammation

208 resistant hypertension (RH) and obstructive sleep apnea (OSA), the blood pressure response to contin

209 tween floppy eyelid syndrome and obstructive sleep apnea (OSA), the diagnostic criteria of floppy eye

210 ular caliber and the severity of obstructive sleep apnea (OSA).

211 lth outcomes are associated with obstructive sleep apnea (OSA).

212 ects with high and low risks for obstructive sleep apnea (OSA).

213 ts, is linked to the severity of obstructive sleep apnea (OSA).

214 a critical pathology underlying obstructive sleep apnea (OSA).

215 irway pressure for patients with obstructive sleep apnea (OSA).

216 ice in patients with symptomatic obstructive sleep apnea (OSA).

217 e most common treatment used for obstructive sleep apnea (OSA).

218 y is the primary risk factor for obstructive sleep apnea (OSA).

219 , we evaluated ten patients with obstructive sleep apnea (OSA).

220 abitus is a major determinant of obstructive sleep apnea (OSA).

221 th chronic insomnia disorder and obstructive sleep apnea (OSA).

222 n symptom of both narcolepsy and obstructive sleep apnea (OSA).

223 ve pharmacological treatment for obstructive sleep apnea (OSA).

224 ulation samples of patients with obstructive sleep apnea (OSA).

225 examined the association between obstructive sleep apnea, other sleep characteristics, and risk of in

226 ss improvement in ACT scores was obstructive sleep apnea (P = 0.016).

227 ne of several traits involved in obstructive sleep apnea pathogenesis and may be a therapeutic target

228 ated the associations of physician-diagnosed sleep apnea (PDSA), which is considered more severe slee

229 erent definitions for positional obstructive sleep apnea (POSA).

230 Alcohol diagnosis, diabetes, hypertension, sleep apnea, prior MI and IHD (all P<0.001) as well as A

231 The sleep apnea questionnaire is an easy method of identifyi

232 leep disorders such as insomnia, obstructive sleep apnea, rapid eye movement sleep behavior disorder,

233 , 13% of men and 21% of women with inpatient sleep apnea received a disability pension.

234 patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure

235 demonstrating the role of sensory neurons in sleep apnea-related atrial fibrillation and the associat

236 ignificant findings reported for obstructive sleep apnea-related physiologic traits in any population

237 ), as well as a significantly higher rate of sleep apnea remission (72.5% vs 49.3%, P < .001) and hig

238 tus, cardiovascular disease, and obstructive sleep apnea, resulting in significant health care resour

239 r characteristics and markers of obstructive sleep apnea severity (hypoxemia, respiratory disturbance

240 ndex (events per hour) to define obstructive sleep apnea severity (normal, <5.0; mild, 5.0-14.9; mode

241 o investigate whether markers of obstructive sleep apnea severity are associated with gray matter cha

242 regression was used to estimate obstructive sleep apnea severity with risk of incident CKD, adjustin

243 ics: reporting any insomnia symptoms, having sleep apnea, sex, body mass index, smoking status, Short

244 substance abuse, age 65 years or older, and sleep apnea should be preassessed and used to help guide

245 gnitive and behavioral deficits occurring in sleep apnea.SIGNIFICANCE STATEMENT Individuals with slee

246 icipants (N=913) underwent an in-home Type 3 sleep apnea study, clinic BP measurements, and anthropom

247 tocols in patients with intermediate-to-high sleep apnea suspicion (most patients requiring a sleep s

248 Sequentially screened patients with sleep apnea suspicion were randomized to respiratory pol

249 uded the Epworth Sleepiness Scale (ESS), the Sleep Apnea Symptoms Questionnaire (SASQ), continuous po

250 The prevalence of obstructive sleep apnea syndrome (OSAS) in patients with nonarteriti

251 Obstructive sleep apnea syndrome (OSAS) is associated with intermitt

252 Obstructive sleep apnea syndrome (OSAS) leads to neurocognitive and

253 Obstructive sleep apnea syndrome (OSAS) represents a substantial dis

254 estigate the correlation between obstructive sleep apnea syndrome (OSAS) risk with periodontal diseas

255 asthma patients with concomitant obstructive sleep apnea syndrome (OSAS) seems to have a favorable im

256 ludes primary snoring through to obstructive sleep apnea syndrome (OSAS), may cause compromise of res

257 ocampus-dependent cognition, and obstructive sleep apnea syndrome (OSAS).

258 s a role in treating snoring and obstructive sleep apnea syndrome (OSAS).

259 emic hypertension, diabetes, and obstructive sleep apnea syndrome between September 2007 and July 201

260 rved a significant prevalence of obstructive sleep apnea syndrome in patients in waiting list for LT,

261 Obstructive sleep apnea syndrome is a highly prevalent disease resul

262 Prevalence of obstructive sleep apnea syndrome was 38% before the LT, 86% at 6 mon

263 ity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory fai

264 thmatics with moderate to severe obstructive sleep apnea syndrome.

265 ease, migraine, hypotension, and obstructive sleep apnea syndrome.

266 is a common disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate the efficac

267 Obesity and obstructive sleep apnea tend to coexist and are associated with infl

268 -disordered breathing study including a home sleep apnea test (ApneaLink Plus).

269 In recent years, a strategy of home sleep apnea testing followed by initiation of autotitrat

270 any patients, OSA can be diagnosed with home sleep apnea testing, which has a sensitivity of approxim

271 grams were edited to simulate Level III home sleep apnea tests (HSAT) with the auto-scored AHI and OD

272 In this review, we discuss the mechanisms of sleep apnea, the evidence that addresses the links betwe

273 Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence.

274 nd research that has addressed the effect of sleep apnea treatment on cardiovascular disease and clin

275 Finally, we review the recent development in sleep apnea treatment options, with special consideratio

276 bstructive sleep apnea with current or prior sleep apnea treatment.

277 Prevalence of severe obstructive sleep apnea was 51% (95% confidence interval, 34-69) in

278 Outpatient sleep apnea was associated with a higher risk of receivi

279 5% confidence interval: 0.22, 0.33 hrs), but sleep apnea was not significantly associated with diary-

280 PDSA, a marker of more severe sleep apnea, was associated with higher risk of incident

281 s with OHS and coexistent severe obstructive sleep apnea), we compared the effectiveness of three yea

282 emia may underlie cardiovascular sequelae of sleep apnea, we evaluated the effects of nocturnal suppl

283 s models tested whether insomnia symptoms or sleep apnea were associated with diary-questionnaire dif

284 2 diabetes, hypertension, dyslipidemia, and sleep apnea were found to be significantly associated wi

285 ially screened patients with OHS with severe sleep apnea were randomized into the above-mentioned gro

286 hospitalized with HF and moderate-to-severe sleep apnea were randomized to ASV plus optimized medica

287 control) on BP in patients with obstructive sleep apnea were selected by consensus.

288 h obesity should be screened for obstructive sleep apnea, which is often undiagnosed and can result i

289 Sleep apnea, which is the periodic cessation of breathin

290 mulation device in patients with obstructive sleep apnea who had difficulty either accepting or adher

291 There were no associations of inpatient sleep apnea with cancer mortality.

292 ovide evidence that treatment of obstructive sleep apnea with continuous positive airway pressure imp

293 r risk factors, the treatment of obstructive sleep apnea with CPAP, but not nocturnal supplemental ox

294 sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment.

295 Evidence supports a causal association of sleep apnea with the incidence and morbidity of hyperten

296 Patients were screened for obstructive sleep apnea with the use of the Berlin questionnaire, an

297 We investigated the association of sleep apnea with uncontrolled BP and resistant hypertens

298 tes and no previous diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5

299 ring without PDSA (HS), a surrogate for mild sleep apnea, with incident AF in white, black, and Hispa

300 SRD, and that fluid removal by UF attenuates sleep apnea without altering uremic status.